Sign up
Pharma Capital

Arix Bioscience to invest another US$5mln in Autolus

Autolus said earlier this week it was looking to raise money from investors, and it has today confirmed plans to raise US$100.8mln through the issue of 4.2mln shares at US$24 each
dollars
Arix’s investment keeps its total stake in Autolus at 7.6%

Biotech investor Arix Bioscience PLC (LON:ARIX) has agreed to invest another £3.8mln (US$5.0mln) in Autolus Therapeutics PLC (NASDAQ:AUTL).

The share purchase will keep Arix’s stake in Autolus at 7.6%, which is valued at £62.6mln.

READ: Arix Bioscience confirms Autolus to launch proposed public offering

In total, Autolus is raising US$100.8mln from investors through the issue of 4.2mln American Depositary Shares (ADS) at US$24.00 apiece.

“Our investment in Autolus today demonstrates our strategy to build world-leading biotech companies through the provision of flexible, long term capital,” said chief executive Joe Anderson.

“We believe Autolus is at the forefront of a revolution in cancer treatment and that its innovative approach to T-cell programming has the potential to offer life-changing therapies for patients.”

Arix backing its winners

“Arix first invested £10mln into Autolus's Series B round in March 2016,” noted analysts at US investment bank Stifel.

“Subsequent financing rounds, the Nasdaq IPO in June 2018 and now this latest equity offering, means Arix has invested £24.6mln so far into Autolus.

“That investment is now valued at £62.6m generating a decent return so far, but with the market effectively discounting the shares during the offering (shares sold at US$24 per ADS vs US$31 per ADS before the offer was announced), we would expect the shares to recover and provide greater value uplift for Arix.”

Arix shares were down 1.3% to 144.1p on Thursday morning.

--Adds analyst comment--

View full ARIX profile View Profile
View All

Related Articles

Social media use
Social first has allowed sites like UNILAD to amass a huge audience with very little capital injection, but what is social first publishing and how is it changing the nature of content and advertising?

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.